Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

SELL
$0.4 - $0.55 $207 - $284
-518 Reduced 65.74%
270 $0
Q3 2022

Nov 10, 2022

SELL
$0.69 - $1.33 $305 - $589
-443 Reduced 35.99%
788 $1,000
Q2 2022

Aug 10, 2022

SELL
$0.92 - $2.25 $2,392 - $5,852
-2,601 Reduced 67.88%
1,231 $1,000
Q1 2022

May 12, 2022

SELL
$1.72 - $5.23 $11,044 - $33,581
-6,421 Reduced 62.63%
3,832 $7,000
Q4 2021

Feb 10, 2022

BUY
$4.65 - $7.75 $16,182 - $26,970
3,480 Added 51.38%
10,253 $49,000
Q3 2021

Nov 10, 2021

BUY
$6.05 - $9.66 $40,976 - $65,427
6,773 New
6,773 $49,000

Others Institutions Holding NLTX

# of Institutions
1
Shares Held
199K
Call Options Held
0
Put Options Held
0

About Neoleukin Therapeutics, Inc.


  • Ticker NLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,579,900
  • Description
  • Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...
More about NLTX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.